A 18 year old male presented with features of Cushing's syndrome including weight gain, facial puffiness, and striae. Laboratory tests confirmed ectopic cortisol secretion from an adrenal tumor. Imaging revealed a large right adrenal mass invading nearby structures with lung metastases. Biopsy supported a diagnosis of metastatic adrenocortical carcinoma. Surgery was not possible and the patient was started on palliative chemotherapy with ketoconazole.
Adrenocortical Carcinoma: Clinical Features & Hormonal Evaluationgourav_singh
This slide contains general information about Adrenocortical Carcinoma, how patients presents with it and information regarding how it can be Hormonally diagnosed.
A presentation about Adrenal gland tumors. This presentation contains 43 slides, and is divided into 3 parts :
1 - Adrenal gland tumors (Introduction).
2 - Imaging Adrenal gland tumors.
3 - Cases.
This presentation was prepared and presented by me in the tutorials of the Radiology Department of Sebha Medical Center.
Adrenocortical Carcinoma: Clinical Features & Hormonal Evaluationgourav_singh
This slide contains general information about Adrenocortical Carcinoma, how patients presents with it and information regarding how it can be Hormonally diagnosed.
A presentation about Adrenal gland tumors. This presentation contains 43 slides, and is divided into 3 parts :
1 - Adrenal gland tumors (Introduction).
2 - Imaging Adrenal gland tumors.
3 - Cases.
This presentation was prepared and presented by me in the tutorials of the Radiology Department of Sebha Medical Center.
Evaluation and management of Stage III Non-Small Cell Carcinoma Lung including Radiotherapy planning. On a Radiation Oncologist Perspective. MD Radiotherapy discussion - CMC, Vellore
Treatment and early outcome of 11 children with hepatoblastoma.Dr./ Ihab Samy
Fouad A. Fouad saleep MD., Ihab samy Fayek MD.
Department of Surgical Oncology – National Cancer Institute – Cairo University - Egypt.
Kasr el-aini medical journal Volume 18, No.4, October 2012.
Laparoscopic adrenalectomy in patients with subclinical cushing syndrome | γι...Γιώργος Ζωγράφος
Abstract:
Background Subclinical Cushing syndrome in patients with adrenal incidentalomas has been associated with an increased prevalence of the metabolic syndrome and car- diovascular risk. The management of these patients, be it conservative or surgical, is still debated, but there is accumulating evidence that surgery is best and that lapa- roscopic adrenalectomy, when possible, is the most pre- ferred procedure. Here we present the short- and long-term results of laparoscopic adrenalectomy for subclinical Cushing syndrome and determine the effect of this proce- dure on components of the metabolic syndrome.
Methods Twenty-nine patients, 8 men and 21 women with adrenal incidentalomas and subclinical Cushing syn- drome who underwent laparoscopic adrenalectomy, were studied retrospectively. They had undergone postoperative follow-up for improvement or worsening of their arterial blood pressure, body weight, and fasting glucose level for a mean period of 77 months.
Results:
Preoperatively, 17 patients (58.6 %) had arterial hypertension, 14 (48.3%) had a body mass index exceeding 27 kg/m2, and 12 (41.4 %) had diabetes melli- tus. Postoperatively, a decrease in mean arterial pressure was found in 12 patients (70.6 %), a decrease in body mass index in 6 patients (42.9 %), and an improvement in gly- cemic control in 5 patients (41.7 %).
Conclusions Laparoscopic adrenalectomy is beneficial in many patients with subclinical Cushing syndrome because it reduces arterial blood pressure, body weight, and fasting glucose levels. Prospective randomized studies are needed to compare laparoscopic adrenalectomy with a conserva- tive approach and to confirm these results.
Dr. Sharfuddin Chowdhury: Tranexamic Acid administration in traumaShakila Rifat
Time since injury is the major factor in preventing Tranexamic Acid (TXA) use in the trauma setting: An observational cohort study from a major trauma centre in a middle income country.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. Mr. KS, 18 y.o. male referred from NSH with
features of cushing’s syndrome
He presented with 6/12 hx of cutaneous striae,
hirsutism (excessive hair growth) truncal obesity,
puffy face, weight gain +/-30kg, fatigue
4. CT scan revealed a large lobulated and enhancing lesion originating from the
right adrenal gland with involvement of retrohepatic IVC & liver and atleast 2 lung
metasteses noted
5. Its appearance, coupled with the patient history, physical
exam, and laboratory data strongly suggested an
unresectable metastatic adrenocortical carcinoma
Patient discharged with palliative chemotherapy-
ketoconazole
6. Mrs. DW, fit 87 y. o. female presented to private with symptomatic
anaemia with unexplained bleeding in about March/ April last year.
She had 4 Gastroscopies, 2 Colonoscopies, a barium follow-through
and a nuclear scan study was suggestive of bleeding from terminal
ileum.
She then had a resection of the terminal ileum but has continued
bleeding.
7. She then had a capsule endoscopy study which was unsatisfactory but did show
some blood in the stomach. some telangiectatic spots were noted and it was
thought that these may be the cause of the bleeding.
Since then she has required regular blood transfusions every month.
She usually presents with melaena without any acute haemodynamic event.
She had a previous left adrenocortical carcinoma which was operated in 1991 in
private.
8. CT Abdomen:
revealed a 6.5 cm relatively vascular mass arising anterior to the upper pole
of the left kidney infiltrating the posterior wall of the stomach just distal to the
OG junction highly suggestive of recurrence of adrenal carcinoma.
CT Guided Biopsy: inadequate
9.
10. Estimated incidence of 0.5-2 per 106 patients per
year
Peaks of age distribution at age <10 and in the 4 th
and 5th decades
Scattered reports of gene associations, but rarity of
lesion precludes clear associations
11. 60-65% are functional and produce hormone excess related symptoms
> rapidly progressive cushing syndrome
> mixed cushing syndrome and an androgenital disorder
> 75%are locally aggressive at the time of diagnosis, median survival of 18
months following diagnosis. Tumor grade important for survival
35-40% are non functional tumors ( or asymptomatic functioning tumors)
> abdominal pain / mass, weight loss, fatigue, nausea
12. Hormonal studies can be a first diagnostic test which
confirms ectopic steroid hormone secretion, leading to an
imaging and tissue diagnosis.
13. 24 hour urinary cortisol exrection
> More than 90% of Cushinoid patients have free cortisol levels greater than
200mcg/ 24 hours. 97% of normals have levels less than 100mcg/ 24 hours
ACTH measured with serum cortisol will demonstrate
ACTH independent nature of hypercortisolism.
14. Other steroids are elevated:
androstenediol and adrosetenedione
DHEA and DHEA-S
11- deoxycortisol
urinary 17- ketosteroids
aldosterone
Many intermediate enzymes are defective or
dysregulated, leading to inefficient steroid production
and precursor buildup
15. Serum Testosterone
Serum DHEA and DHEA-S
24 hour urinary ketosteroids
Plasma estradiol and/ or estrone
Plasma aldosterone/ renin
Urinary catecholamines/ metanephrines in all
patients
16. CT detects 98% of adrenal carcinomas
MRI scanning can also provide vascular invasion/
tumor thrombosis information.
Also provides many incidentalomas
Malignant lesions tend to be > 5cm, have irregular
shapes/ blurred margins, and be heterogeneously
enhancing.
17. Stage I — Disease confined to the adrenal gland and
<5 cm in diameter (approx 20%)
Stage II — Disease confined to the adrenal gland and
>5 cm in diameter (approx 20%)
Stage III — Local invasion that does not involve
adjacent organs or regional lymph nodes(approx20%)
Stage IV — Distant metastases or invasion into adjacent
organs plus regional lymph nodes (approx 40%)
21. Unresectable tumors include those that invade the
celiac plexus/ vascular structures/ SMA/ aorta
22. In a case review of 46 patients at MSKCC, 3 histologic
factors correlated with survival:
tumor> 12cm
6 or more mitotic figures/ 10hpf
presence of histologic evidence of intratumoral
hemorrhage
5 year survivals:
▪ 0 factors: 83%
▪ 1 factor: 42%
▪ 2 factors: 33%
23. There are scattered case reports demonstrating
improved pain when palliative XRT used for
localized lesions
24. Review of the literature reveals case reports,
retrospective treatment data, and reviews.
A few phase II trials do exist from some
cooperative or national groups
No true modern- design controlled phase III trials
exist
25. 1,1- dichloro-2-(o-chlorophenyl) ethane (o,p-DDD).
Chemical relative to DDT
It produces selective adrenocortical necrosis in both the adrenal tumor and
metastases
Reported in 1960 by Bergenstal
Subsequent NCI study in 1966 in 138 patients
Noted “reduced symptoms” in about half the patients
Another study (Haak, Netherlands) retrospectively looked at a series of 96
patients treated from 1959- 92
62 patients were treated with mitotane during their course
Of the 30 who achieved serum levels >14mg/L, they had a greater survival
27. Italian series showed no
survival difference
between two groups of
completely resected
patients
Effect of adjuvant mitotane (n = 11) compared with no treatment (n = 15) on the
disease-free interval in patients with localized or regional adrenocortical carcinoma.
28. Of 19 patients treated at MD Anderson cancer center, 8
patients received it adjuvantly, 5 patients received it
transiently, 6 patients did not receive any.
Disease free interval was actually shortest in the adjuvant
group
29. Various systemic cytotoxics have been used for
advanced disease, usually for those failing
mitotane.
Most studied have been Etoposide, cisplatin,
and adriamycin.
Paclitaxel and Temozolamide have recently
demonstrated antitumor activity in vitro
30. Original studies utilized Cisplatin and Doxorubicin with
Cyclophosphamide or 5-FU. Response Rate was 20%
Cisplatin/ Etoposide reported to have an 11% response
rate
Phase II studies with varying reported efficacy exist
31.
32. Italian study
28 patients enrolled
Etoposide (100mg/ m2) d5-7; Doxorubicin (20mg/ m2) d1,8; Cisplatin
(40mg/ m2) d1,9 every 4 weeks
Concomitant mitotane up to 4g/ day
Complete Response in 2 patients
Partial Response in 13 patients
Overall response of 54%
Stable disease in 8, progessive in 5
33. Recurrences that are amenable to re- operation
may be resected for long term survival
5 year survivals compare from 57% in those
amenable to resection to 0% for those who are not
34. Italian registry: 140 resections
Recurrences in 52 (37%)
▪ Locally in 13
▪ Distant in 25
▪ Local + Distant in 14
20 patients underwent re- resection
▪ 5 yr survival of 50% in those resected
▪ 5 yr survival of 8% in those not resected
35. MSKCC: 47 patients with recurrent/ metastatic disease
Patients who had a complete second resection had a
median survival of 74 months (5-year survival, 57%),
whereas those with incomplete second resection had a
median survival of 16 months (5-year survival, 0%).
MSKCC: Memorial Sloan Kettering Cancer Centre
36. Adrenocortical carcinoma is a rare disease that often
presents late
Primary curative therapy is surgical
No role for adjuvant chemotherapy has been demonstrated
to date
Palliative therapy with mitotane may be useful; its palliative
effect may be entirely due to adrenolytic effect
37. Reoperation appears to be the only long term curative
option in recurrent cases
Cytotoxic chemotherapy in the advanced/ metastatic
setting has not been definitively demonstrated to be useful
in controlled trials
EDP-M may be useful in metastatic settings; more
evaluation is needed
Editor's Notes
Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab. 1999 Apr;84(4):1488-9. The role of mitotane as adjuvant treatment for adrenocortical carcinoma is controversial (1, 2, 3, 4, 5, 6, 7, 8). Our experience with adjuvant mitotane (8), as that of others (3, 4, 5, 6), indicates that it is not beneficial in terms of either disease freedom or survival. We expanded our observation, and, of 59 consecutive patients (36 females, 23 males) with adrenocortical carcinoma (34 functioning and 25 nonfunctioning), 26 (44%) with localized or regional disease (median tumor size, 8.0 cm; range, 4.6–25.0 cm) underwent complete resection of the tumoral mass. Of these, 11 patients (group 1: 7 females and 4 males) received mitotane (o,p'-DDD, Lysodren, Bristol-Myers Squibb) postoperatively at doses of 4–8 g daily, whereas 15 patients (group 2: 9 females and 6 males) were given no medical treatment. The two groups were similar with regard to sex, age, tumor size, functional status, and tumor staging at diagnosis. Six patients of group 1 were free of disease at last follow-up (range: 6–82 months after surgery), and 5 developed metastases or recurrences (disease free-intervals of 4–29 months); 3 of them died of the disease 24–40 months after diagnosis. Of group 2, 6 were free of disease at last follow-up (range, 14–74 months after surgery), and 9 developed metastases (disease free-intervals of 8–60 months), 8 of them died during follow-up (survival: 15–104 months). Cumulative disease-free interval and survival rates, estimated with the Kaplan-Meyer method and compared with the log-rank test, were not significantly different between the two groups (2 = 0.26, df = 1, P NS; and 2 = 1.15, df = 1, P NS, respectively; Fig. 1). Owing to these disappointing results and the side-effects of mitotane, which significantly worsen quality of life of patients, we would not advocate mitotane as adjuvant treatment of adrenocortical carcinoma. However, prospective studies are needed to evaluate the real efficacy of this compound.
Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al.: Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71 (10): 3119-23, 1993. [PUBMED Abstract] BACKGROUND. Adrenocortical carcinoma is a rare and aggressive disease with a poor prognosis. Adjuvant mitotane administration has been suggested as a strategy that might improve the outcome of patients with localized disease. METHODS. The authors analyzed the clinical outcome of patients with localized or regional adrenocortical cancer. The study included 19 patients who were registered at M.D. Anderson Cancer Center during a 3-year period and who had localized or regional disease at the time of surgery. Of these, eight patients received mitotane postoperatively and continued the drug until their last contact or recurrence (Group A, adjuvant); five patients began taking mitotane after surgery but discontinued it after 2-12 months for reasons unrelated to the disease (Group P, postoperative); and six patients did not receive mitotane (Group N, no mitotane). All patients have been followed for at least 12 months. RESULTS. The treatment groups differed significantly in their time to recurrence; the disease-free interval was shortest in Group A (P = 0.0055, by log-rank test). There was no statistical difference in survival among the groups, but the profile remained unfavorable for Group A. The 2-year survival rate was 100% for Groups N and P but only 43% for Group A. Of the potentially confounding factors, gender, age, steroid hypersecretion, and tumor size, none had any influence on recurrence or survival rates. CONCLUSIONS. These findings do not support the conclusion that adjuvant mitotane is beneficial in patients with localized or regional adrenocortical cancer. Neither the disease-free interval nor survival was improved by the drug. The authors suggest that alternative therapeutic strategies be explored for the management of these patients.
Jensen JC, Pass HI, Sindelar WF, et al.: Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg 126 (4): 457-61, 1991. In a retrospective, nonrandomized comparison of patients with first recurrence of adrenocortical cancer, 18 patients were treated with chemotherapy (primarily mitotane) and 15 patients were treated with surgical resection plus similar chemotherapy. Surgical resection of recurrent adrenocortical cancer was often extensive, with morbidity in 20% of patients and no mortality. Mitotane therapy was ineffective at controlling tumor growth. Median survival from the time of diagnosis for all patients was only 23 months and no patient was cured. Disease-free interval greater than 12 months was associated with prolonged survival, but it only occurred in six patients (18%), with a similar frequency in both treatment groups. Surgical resection of recurrent disease was associated with prolonged survival from the time of first recurrence. The potential benefit of this resection was evident in the 5 patients (33%) who were able to live greater than 5 years from the time of first recurrence with improvement in symptoms and signs of hypercortisolism. Although no patient with recurrent adrenal cancer could be cured, resection of recurrent disease was associated with a slight prolongation of survival and good palliation of Cushing's syndrome.